… in a phase II study conducted at the University of Pittsburgh Cancer Institute [24]. Thirty-nine …
undifferentiated head and neck cancer received three cycles of induction therapy with TPE, …

As therapy for locoregionally advanced head and neck cancer (HNC) has evolved, treatment
has become increasingly aggressive and cure rates have risen. However, survival still …

… Our institution has recently initiated a phase I study of docetaxel plus cisplatin plus everolimus
(RAD001) as induction therapy (TPR) for this patient population [54]. Everolimus is an …

… The most common induction chemotherapy combination employed is cisplatin and … neck
squamous cell cancer was tested. This report described the response to three different induction …

… to salvage therapy for advanced head and neck cancer. … that evolved was the use of induction
or neoadjuvant chemotherapy. The … -induced tumor shrinkage might improve local control. …

… two studies of induction chemotherapy in advanced head and neck cancer. The first study …
single agents to those with recurrent cancer of the head and neck. Oncovin was added to halt …

… induction chemotherapy have historically made this approach attractive as well. This manuscript
reviews key analyses in the literature charting the evolution of induction … therapy option …

… Induction chemotherapy in advanced head and neck cancer. Arch Otolaryngol Head Neck
… Adjuvant chemotherapy in advanced bead and neck cancer: An update. Am J Surg 144:432-…

… , “Can induction therapy possibly interfere with the benefit of subsequent therapy? Yes.” …
able to provide data on the nature of subsequent therapy for these patients. In fact, as seen …

… -targeted therapies and should therefore be taken into consideration for future therapeutic
design. … that hypoxia-targeted therapy is likely to have in head and neck cancer as a chemo/…